ArticleThe FEBS journal2026
Mechanistic insights into HapC: A key enzyme in prodiginine biosynthesis in Hahella chejuensis.
Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Research to understand the enzymatic machinery underlying the biosynthesis of red prodigiosin, a potent secondary metabolite with significant biological activity, led to the identification of HapC, an enzyme from the marine bacterium Hahella chejuensis. In this study, we demonstrated the catalytic capability of HapC in synthesizing a diverse array of short-chain prodiginines through the condensation of various 2-methyl-3-amylpyrrole (MAP) analogs with 4-methoxy-2,2'-bipyrrole-5-carboxaldehyde (MBC). Six prodiginines, all non-native to HapC, were enzymatically synthesized in vitro, including two analogs, 3,4-dimethyl-6-methoxyprodiginine and 2-ethyl-6-methoxyprodiginine, that have not been successfully produced by any prodigiosin-forming enzyme to date, demonstrating the subtle differences in the products formed by HapC. Constructing a structural model of HapC and performing ligand docking simulations with representative ligands corresponding to different reaction steps, including an ATP analog, a phosphorylated MBC, and a prodiginine product, revealed catalytic residues in the two active sites of HapC. To extend from local catalytic interactions to the global mechanistic level, a comparative structural analysis with the homologous rifampin phosphotransferase from Listeria monocytogenes was applied to infer domain dynamics in HapC. A well-defined three-phase catalytic cycle was delineated, highlighting the role of domain rearrangements and phosphotransfer mediated by the conserved histidine residue H859. These findings enhance our understanding of HapC, with the potential to diversify prodiginine libraries and guide rational drug design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.